Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s stock price reached a new 52-week high on Friday . The stock traded as high as C$2.62 and last traded at C$2.46, with a volume of 666739 shares trading hands. The stock had previously closed at C$1.95.
Medicenna Therapeutics Stock Performance
The firm has a market cap of C$173.40 million, a PE ratio of -10.78 and a beta of 1.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 5.00. The firm’s 50 day moving average price is C$1.51 and its two-hundred day moving average price is C$0.81.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Featured Articles
- Five stocks we like better than Medicenna Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Stocks Leading the U.S. Agriculture Comeback
- Investing in Construction Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Consumer Discretionary Stocks Explained
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
